<DOC>
	<DOCNO>NCT01574885</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Aerosal® compare placebo treatment prognosis sub-obstructive adenotonsillar hypertrophy present least six month .</brief_summary>
	<brief_title>Efficacy Aerosal® Treatment Sub-Obstructive Adenotonsillar Hypertrophy Related Diseases</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>SubObstructive Adenotonsillar Hypertrophy last least six month associate sleep disorder breathing ( respiratory pause sleepapnea ) and/or recurrent seromucus otitis Suspension 3 month date immunosuppressive treatment ( cyclosporin , systemic steroid ) Patients acute bronchopulmonary disease , tuberculosis , severe hypertension , hyperthyroidism , cancer ( chemotherapy ) , intoxication , heart failure , bronchial asthma . Iodine allergy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>adenotonsillar hypertrophy</keyword>
	<keyword>salt</keyword>
	<keyword>sodium chloride</keyword>
</DOC>